Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin.

Agudo-López A, Prieto-García E, Alemán J, Pérez C, Díaz-García CV, Parrilla-Rubio L, Cabrera S, Navarro-Ranninger C, Cortés-Funes H, López-Martín JA, Agulló-Ortuño MT.

Mol Cancer. 2017 Feb 23;16(1):45. doi: 10.1186/s12943-017-0618-7.

2.

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Manso L, Palomo AG, Pérez Carrión R, Cassinello J, Gallegos Sancho I, Chacón López-Muñiz I, Olier C, Fernández-Aramburo A, Llorca C, González X, Llorente R, Torregrosa D, Álvarez I, Gálve E, Bueno C, Garau I, García MJ, González-Santiago S, Ballesteros AI, Blanco E, Galán A, González S, Perelló A, Cortés-Funes H, Grávalos C.

Anticancer Res. 2015 Dec;35(12):6941-50.

PMID:
26637920
3.

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J.

Eur J Cancer. 2015 Aug;51(12):1481-9. doi: 10.1016/j.ejca.2015.03.018. Epub 2015 Jun 11.

PMID:
26074397
4.

Risk factors associated with Clostridium difficile infection in adult oncology patients.

Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, Galera Lopez MM, Orellana-Miguel MÁ, Díaz-García CV, Cortijo-Cascajares S, Cortes-Funes H, Agulló-Ortuño MT.

Support Care Cancer. 2015 Jun;23(6):1569-77. doi: 10.1007/s00520-014-2506-7. Epub 2014 Nov 20.

PMID:
25410088
5.

Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.

Díaz-García CV, Agudo-López A, Pérez C, Prieto-García E, Iglesias L, Ponce S, Rodríguez Garzotto A, Rodríguez-Peralto JL, Cortés-Funes H, López-Martín JA, Agulló-Ortuño MT.

Tumour Biol. 2015 Feb;36(2):1199-206. doi: 10.1007/s13277-014-2729-8. Epub 2014 Oct 25.

PMID:
25344212
6.

Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.

García-Escobar I, Parrilla L, Ortega LM, Castellanos D, Pallarés MA, Cortés-Funés H.

Mol Clin Oncol. 2014 Nov;2(6):923-926. Epub 2014 Jul 29.

7.

Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

Agulló-Ortuño MT, Díaz-García CV, Agudo-López A, Pérez C, Cortijo A, Paz-Ares L, López-Ríos F, Pozo F, de Castro J, Cortés-Funes H, López Martín JA.

J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53. doi: 10.1007/s00432-014-1787-z. Epub 2014 Aug 1.

PMID:
25081930
8.

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M, Cortes J.

Breast. 2014 Oct;23(5):656-62. doi: 10.1016/j.breast.2014.06.017. Epub 2014 Jul 19.

PMID:
25047747
9.

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.

Rodriguez Garzotto A, Cortijo Casacajares S, Pernaut C, Ruiz Ares GJ, Otero Blas I, Heine O, Turner M, Rebollo Laserna F, Cortes Funes H, Lorenz A.

J Blood Med. 2014 Apr 28;5:43-8. doi: 10.2147/JBM.S57887. eCollection 2014. Erratum in: J Blood Med. 2014;5:129. Cortijo Casacajares, Susana [added]; Pernaut, Cristina [added]; Ruiz Ares, Gustavo Javier [added]; Otero Blas, Irene [added]; Cortes Funes, Hernan [added].

10.

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, Muñoz C, Vega E, Calderón MJ, Sancho B, Cortes-Funes H.

Breast. 2014 Jun;23(3):201-8. doi: 10.1016/j.breast.2014.01.016. Epub 2014 Mar 1. Review.

11.

Chemotherapy for cholangiocarcinoma: An update.

Ramírez-Merino N, Aix SP, Cortés-Funes H.

World J Gastrointest Oncol. 2013 Jul 15;5(7):171-6. doi: 10.4251/wjgo.v5.i7.171.

12.

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.

Ciruelos E, Cortes-Funes H, Ghanem I, Manso L, Arteaga C.

Anticancer Drugs. 2013 Sep;24(8):769-80. doi: 10.1097/CAD.0b013e328363adc5. Review.

PMID:
23838677
13.

Guidelines for the management of breakthrough pain in patients with cancer.

Caraceni A, Davies A, Poulain P, Cortés-Funes H, Panchal SJ, Fanelli G.

J Natl Compr Canc Netw. 2013 Mar;11 Suppl 1:S29-36.

PMID:
23520183
14.

Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.

Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C, Tabernero J, Coronado C, García M, Soto Matos-Pita A, Miguel-Lillo B, Cullell-Young M, Iglesias Dios JL, Paz-Ares L.

Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83. doi: 10.1007/s00280-013-2170-5. Epub 2013 May 5.

PMID:
23645288
15.

DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.

Díaz-García CV, Agudo-López A, Pérez C, López-Martín JA, Rodríguez-Peralto JL, de Castro J, Cortijo A, Martínez-Villanueva M, Iglesias L, García-Carbonero R, Fresno Vara JA, Gámez-Pozo A, Palacios J, Cortés-Funes H, Paz-Ares L, Agulló-Ortuño MT.

Carcinogenesis. 2013 May;34(5):1031-8. doi: 10.1093/carcin/bgt022. Epub 2013 Jan 24.

PMID:
23349018
16.

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

Manso L, Valdiviezo N, Sepúlveda J, Ciruelos E, Mendiola C, Ghanem I, Vega E, Manneh R, Dorta M, Cortés-Funes H.

Clin Transl Oncol. 2013 Jun;15(6):467-71. doi: 10.1007/s12094-012-0954-4. Epub 2012 Dec 21.

PMID:
23263907
17.

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.

Gravalos C, Salut A, García-Girón C, García-Carbonero R, León AI, Sevilla I, Maurel J, Esteban B, García-Rico E, Murias A, Cortés-Funes H.

Clin Transl Oncol. 2012 Aug;14(8):606-12. doi: 10.1007/s12094-012-0843-x. Epub 2012 Jul 19.

18.

Behaviour of breast cancer molecular subtypes through tumour progression.

Castaneda CA, Andrés E, Barcena C, Gómez HL, Cortés-Funés H, Ciruelos E.

Clin Transl Oncol. 2012 Jun;14(6):481-5. doi: 10.1007/s12094-012-0827-x.

PMID:
22634538
19.

Biological markers of cisplatin resistance in advanced testicular germ cell tumours.

García-Velasco A, Durán I, García E, Tarón M, Ballestín C, Castellanos D, Cortés-Funés H, Paz-Ares L.

Clin Transl Oncol. 2012 Jun;14(6):452-7. doi: 10.1007/s12094-012-0823-1.

PMID:
22634534
20.

First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study.

Thomssen C, Pierga JY, Pritchard KI, Biganzoli L, Cortes-Funes H, Petráková K, Kaufman B, Duenne A, Smith I.

Oncology. 2012;82(4):218-27. doi: 10.1159/000336892. Epub 2012 Apr 12.

PMID:
22508241
21.

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.

Yap TA, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martin JA.

Br J Cancer. 2012 Apr 10;106(8):1379-85. doi: 10.1038/bjc.2012.99.

22.

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.

Cortés J, Caralt M, Delaloge S, Cortes-Funes H, Pierga JY, Pritchard KI, Bollag DT, Miles DW.

Eur J Cancer. 2012 Mar;48(4):475-81. doi: 10.1016/j.ejca.2011.11.021. Epub 2011 Dec 22.

PMID:
22196033
23.

Implication of miRNA in the diagnosis and treatment of breast cancer.

Castañeda CA, Agullo-Ortuño MT, Fresno Vara JA, Cortes-Funes H, Gomez HL, Ciruelos E.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1265-75. doi: 10.1586/era.11.40. Review.

PMID:
21916580
24.

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Ann Oncol. 2012 Apr;23(4):1016-22. doi: 10.1093/annonc/mdr367. Epub 2011 Aug 23.

PMID:
21865152
25.

Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.

Smith I, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, Saracchini S, Nisenbaum B, Pelaez I, Duenne AA, Pritchard KI.

Breast Cancer Res Treat. 2011 Nov;130(1):133-43. doi: 10.1007/s10549-011-1695-8. Epub 2011 Aug 10.

PMID:
21830015
26.

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

Pardo B, Salazar R, Ciruelos E, Cortés-Funes H, García M, Majem M, Montes A, Cuadra C, Soto-Matos A, Lebedinsky C, Alfaro V, Paz-Ares L.

Med Oncol. 2012 Sep;29(3):2240-50. doi: 10.1007/s12032-011-9979-8. Epub 2011 Jun 10.

PMID:
21660618
27.

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.

Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J, Colomer R, Cortés-Funes H, Jimeno A.

Clin Transl Oncol. 2011 Mar;13(3):179-84. doi: 10.1007/s12094-011-0637-6.

PMID:
21421462
28.

Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer.

Cortes-Funes H, Ghanem I.

Expert Rev Anticancer Ther. 2011 Feb;11(2):165-8. doi: 10.1586/era.10.234.

PMID:
21342034
29.

The role of RANK-ligand inhibition in cancer: the story of denosumab.

Castellano D, Sepulveda JM, García-Escobar I, Rodriguez-Antolín A, Sundlöv A, Cortes-Funes H.

Oncologist. 2011;16(2):136-45. doi: 10.1634/theoncologist.2010-0154. Epub 2011 Feb 1. Review.

30.

Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives.

García-Escobar I, Sepúlveda J, Castellano D, Cortés-Funes H.

Crit Rev Oncol Hematol. 2011 Oct;80(1):100-13. doi: 10.1016/j.critrevonc.2010.10.006. Epub 2010 Dec 13. Review.

PMID:
21146422
31.

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanović A, Cortes-Funes H, Buesa JM.

Invest New Drugs. 2012 Apr;30(2):729-40. doi: 10.1007/s10637-010-9561-9. Epub 2010 Oct 20.

PMID:
20960029
32.

The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.

Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM.

Cancer Metastasis Rev. 2010 Dec;29(4):751-9. doi: 10.1007/s10555-010-9261-0. Review.

PMID:
20922461
33.

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group.

Ann Oncol. 2011 Mar;22(3):595-602. doi: 10.1093/annonc/mdq430. Epub 2010 Sep 5.

PMID:
20819780
34.

Diagnosis of unknown primary cancer based on molecular techniques may influence therapeutic approach and improve survival.

Homet B, Hitt R, Ghanem I, Cortés-Funes H.

Clin Transl Oncol. 2010 Aug;12(8):574-5. doi: 10.1007/s12094-010-0556-y.

PMID:
20709655
35.

Expression of EGFR, HER-2/neu and KIT in germ cell tumours.

Durán I, García-Velasco A, Ballestín C, García E, Martínez-Tello F, Pond GR, García-Carbonero R, Cortés-Funés H, Paz-Ares L.

Clin Transl Oncol. 2010 Jun;12(6):443-9. doi: 10.1007/s12094-010-0532-6.

PMID:
20534400
36.

Biliary cystadenocarcinoma with mesenchymal stroma.

Gómez-Martín C, Rodríguez A, Malón D, Cortés-Funes H.

Clin Transl Oncol. 2010 Mar;12(3):234-7. doi: 10.1007/s12094-010-0495-7.

PMID:
20231130
37.

Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

Ciruelos EM, Cortés J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, Baselga J.

Ann Oncol. 2010 Jul;21(7):1442-7. doi: 10.1093/annonc/mdp536. Epub 2009 Nov 25.

PMID:
19940004
38.

Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer.

González-Billalabeitia E, Calzas J, Castellano D, Mendiola C, Bezares S, Valentín V, Hornedo J, Ciruelo E, Cortés-Funes H.

Breast J. 2009 Sep-Oct;15(5):551-3. doi: 10.1111/j.1524-4741.2009.00783.x. Epub 2009 Aug 4. No abstract available.

PMID:
19671111
39.

Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma.

González-Billalabeitia E, Hitt R, Fernández J, Conde E, Martínez-Tello F, Enríquez de Salamanca R, Cortés-Funes H.

Clin Transl Oncol. 2009 Jul;11(7):479-83.

PMID:
19574207
40.

The role of antiangiogenesis therapy: bevacizumab and beyond.

Cortés-Funes H.

Clin Transl Oncol. 2009 Jun;11(6):349-55. Review.

PMID:
19531449
41.

Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.

Fumoleau P, Cortés-Funes H, Taleb AB, Chan S, Campone M, Pouget JC, Tubiana-Hulin M, Slabber CF, Caroff-Paraïso I, Alberts AS, Ben Ayed F.

Am J Clin Oncol. 2009 Aug;32(4):375-80. doi: 10.1097/COC.0b013e31818f2d2f.

PMID:
19487917
42.

Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer.

Garrido-Laguna I, Amador ML, Ruiz J, Cortés-Funes H.

Clin Transl Oncol. 2009 Mar;11(3):183-5.

PMID:
19293057
43.

Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.

Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, Mayordomo JI, Gil M, Benavides M, Cirera L, Ojeda B, Rodríguez CA, Trigo JM, Vazquez J, Regueiro P, Dorado JF, Baselga J; Spanish Breast Cancer Cooperative Group SOLTI.

Clin Cancer Res. 2009 Jan 1;15(1):307-14. doi: 10.1158/1078-0432.CCR-08-1113. Erratum in: Clin Cancer Res. 2009 Mar 1;15(5):1843.

44.

Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.

García-Velasco A, Mendiola C, Sánchez-Muñoz A, Ballestín C, Colomer R, Cortés-Funes H.

Clin Transl Oncol. 2008 Jun;10(6):367-71.

PMID:
18558584
45.

[Contribution of PET-CT in diagnostic-therapeutic decisions in Medical Oncology].

Cortés-Funes H.

Rev Esp Med Nucl. 2008 Mar-Apr;27(2):79-82. Spanish. No abstract available.

46.

Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.

Jimeno A, Grávalos C, Escudero P, Sevilla I, Vega-Villegas ME, Alonso V, Juez I, García-Carbonero R, Bovio H, Colomer R, Cortés-Funes H.

Clin Transl Oncol. 2008 Jan;10(1):52-7.

PMID:
18208793
47.

Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.

Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U, Cortes-Funes H, Baselga J.

Clin Cancer Res. 2008 Jan 1;14(1):215-23. doi: 10.1158/1078-0432.CCR-07-1053.

48.

Role of anthracyclines in the era of targeted therapy.

Cortés-Funes H, Coronado C.

Cardiovasc Toxicol. 2007;7(2):56-60. Review.

PMID:
17652804
49.

Prognostic value of KIT expression in small cell lung cancer.

López-Martin A, Ballestín C, Garcia-Carbonero R, Castaño A, Lopez-Ríos F, López-Encuentra A, Sánchez-Cespedes M, Castellano D, Bartolomé A, Cortés-Funes H, Paz-Ares L.

Lung Cancer. 2007 Jun;56(3):405-13. Epub 2007 Apr 8.

PMID:
17420067
50.

Primary pulmonary artery sarcoma: report of three cases and review of the literature.

Manso L, Alvarez E, Quintela M, Cortes-Funes H, Hitt R.

Clin Lung Cancer. 2007 Jan;8(4):277-81.

PMID:
17311694

Supplemental Content

Loading ...
Support Center